What Happened to Peptide Sciences? The Shutdown Explained

Peptide Sciences was a US-based research peptide supplier that operated for over a decade, building a reputation as one of the more reliable domestic sources for research-grade peptides. They offered a wide catalog — from popular healing peptides like BPC-157 and TB-500, to GH secretagogues, cognitive peptides, and GLP-1 compounds including semaglutide and tirzepatide.

For many researchers and practitioners in the peptide community, Peptide Sciences was a go-to source. They were known for publishing Certificates of Analysis (CoA) on their products, offering reasonable pricing, and maintaining domestic shipping speeds that foreign suppliers couldn't match. Their longevity in an industry with high turnover earned them a level of trust that was unusual.

The shutdown of a company with that reputation is significant — and it isn't an isolated incident. It is part of a broader wave of closures and restrictions hitting the US peptide market.

Peptide Sciences ceased operations in 2025, with the website going dark and order processing halting. The closure did not come with a formal public announcement — which is common for companies in this regulatory environment, as operators prefer to quietly exit rather than attract further scrutiny.

Customers began reporting failed orders, unresponsive customer service, and an inaccessible website in the same period that the FDA was escalating enforcement actions against domestic peptide suppliers at scale. The timing was not coincidental.

The regulatory environment for research peptides in the United States has changed dramatically over the past several years. Several converging forces have made operating a domestic peptide business increasingly difficult — and in many cases, untenable.

The cumulative effect of these pressures has eliminated a significant portion of the domestic US research peptide supply chain. Peptide Sciences is one of the higher-profile casualties, but they are far from alone. Dozens of similar businesses have quietly closed over the same period.

The closure of established suppliers like Peptide Sciences creates real problems for the research community. The concern is not just convenience — it's quality and safety. When trusted, established suppliers exit the market, researchers are pushed toward newer, less-established sources with shorter track records and less rigorous quality control.

The well-documented risk of counterfeit or underdosed research peptides increases substantially when the market is disrupted. Independent testing of peptides from anonymous or unverified sources has frequently found incorrect concentrations, contamination, or outright substitution with cheaper compounds.

Researchers who relied on Peptide Sciences for consistent, CoA-backed product quality now need to identify a replacement supplier that meets the same standard — which is a meaningful challenge in a market where quality varies enormously.

Our Recommended Alternative: Base Peptides

With Peptide Sciences no longer operating, researchers need a reliable, quality-conscious source. Based on our evaluation of the current market, Base Peptides is our top recommendation for researchers seeking a trusted domestic-equivalent quality supplier.

Before purchasing from any supplier, we recommend verifying that they provide independent third-party testing results and a clear Certificate of Analysis for each batch. Never purchase peptides from sources that cannot provide quality documentation — the quality gap in this market is significant.